Realizou-se um estudo estrutura-atividade sobre os efeitos citoprotetor/citotóxico de 5 flavonóides envolvendo processos mitocondriais, com ênfase na apoptose. Nossos resultados mostram que a dupla ligação na posição 2-3 / grupos 3-OH em conjugação com a função 4-oxo no anel C da estrutura dos flavonóides parece favorecer a interação destes compostos com a membrana mitocondrial, diminuindo a sua fluidez, e tanto inibindo a cadeia respiratória das mitocôndrias, quanto causando desacoplamento. Por outro lado, a estrutura o-di-OH no anel B parece favorecer a inibição da cadeia respiratória, sendo que a ausência desta estrutura parece favorecer a atividade desacopladora. Os flavonóides que não afetaram a respiração mitocondrial, induziram a transição de permeabilidade mitocondrial. A capacidade dos flavonóides em liberar o Ca2+ acumulado pelas mitocôndrias correlaciona-se com a sua capacidade de afetar a respiração mitocondrial e sua inabilidade em induzir a transição de permeabilidade mitocondrial. Já os dados referentes aos estudos da atividade protetora contra a formação de radicais livres demonstraram que a quercetina, luteolina e a galangina foram substancialmente mais potentes que a taxifolina e a catequina em conferir proteção contra a lipoperoxidação, embora somente a quercetina tenha sido um efetivo seqüestrador tanto de DPPH?, quanto de O2?-. Esses resultados sugerem que a dupla ligação na posição 2-3 em conjugação com a função 4-oxo na estrutura dos flavonóides são os fatores mais importantes na atividade antioxidante dos flavonóides sobre as mitocôndrias. Ainda, a presença da estrutura o-di-OH no anel B, conforme observado na quercetina, favorece essa atividade via seqüestro de O2?-, enquanto que a ausência dessa característica estrutural na galangina, a favorece via diminuição da fluidez de membrana e/ou desacoplamento mitocondrial. Os ensaios realizados para avaliar o efeito dos flavonóides sobre as células HepG2 mostraram que galangina, luteolina e quercetina são capazes de induzir morte celular. Esse efeito parece estar associado à dissipação do potencial de membrana mitocondrial e à diminuição na capacidade energética celular, mais pronunciada no caso dos dois primeiros; porém, como essa diminuição na concentração de ATP não é drástica, a morte celular pode ocorrer por apoptose. Os experimentos realizados para avaliar essa possibilidade sugerem uma ativação das caspases via mitocôndria, observada pelo aumento das atividades de caspase -9 e -3 e também pela exposição de fosfatidil serina. A taxifolina que não apresentou capacidade de produzir dano celular, apresentou, por outro lado, capacidade de prevenir parcialmente a diminuição de viabilidade das células HepG2 induzida pelo pró-oxidante t-butilhidroperóxido, aparentemente por meio de sua atividade antioxidante que inibiu, também de forma parcial, o acúmulo de espécies reativas de oxigênio. / We carried out a structure-activity study addressing the protective/toxic effects of 5 flavonoids (quercetin, taxifolin, luteolin, catechin and galangin) upon mitochondrial aspects with emphasis on the mechanisms potentially involved in cell apoptosis. The major findings were: The 2,3 double bond/3-OH group in conjugation with the 4-oxo function on the C-ring in the flavonoid structure seems favour the interaction of these compounds with the mitochondrial membrane, decreasing its fluidity either inhibiting the respiratory chain of mitochondria or causing uncoupling; while the o-di-OH on the B-ring seems favour the respiratory chain inhibition, the absence of this structure seems favour the uncoupling activity. The flavonoids not affecting the respiration of mitochondria induced MPT. The ability of flavonoids to induce the release of mitochondria-accumulated Ca2+ correlated well with their ability to affect mitochondrial respiration on the one hand, and their inability to induce MPT, on the other. The data concerning the protective activity against the free radical formation showed that quercetin, luteolin and galangin were far more potent than taxifolin and catechin in affording protection against lipid peroxidation, although only quercetin was an effective scavenger of both DPPH? and O2?-. These results suggest that the 2,3-double bound in conjugation with the 4-oxo function in the flavonoid structure are major determinants of the antioxidant activity of flavonoids on mitochondria, the presence of an o-di-OH structure on the B-ring, as occurring in quercetin, favouring this activity via O2?- scavenging, while the absence of this structural feature in galangin, favouring it via decrease in membrane fluidity and/or mitochondrial uncoupling. The assays addressing the flavonoids effects on HepG2 cells showed that galangin, luteolin and quercetin are able to induce cell death. This effect appears to be linked to the mitochondrial membrane potential dissipation and consequent decrease in the cellular energy charge, more pronounced for the galangin or luteolin treatment. However, since this decrease in ATP content is not drastic, the apoptosis process can occur. The set of experiments performed in order to evaluate this possibility demonstrated caspases-9 and -3 activation and also phosphatidylserine exposure on the cell membrane. On the other hand, taxifolin, that did not present ability to induce injury to the cell, was able to partially inhibit a viability decrease of HepG2 cell exposed to the pro-oxidant t-butylhydroperoxide, probably on account of its capacity to partially decrease ROS formation.

Le glutamate est le principal neurotransmetteur excitateur du système nerveux central. Il est responsable de la majorité des transmissions synaptiques. En revanche, cet acide aminé naturel est aussi impliqué dans de nombreuses neuropathologies notamment en cas de surconcentration au niveau des synapses. Les récepteurs métabotropiques du glutamate, capables de moduler la transmission synaptique, constituent des cibles thérapeutiques prometteuses. Ces récepteurs sont divisés en trois groupes et notre laboratoire s’est focalisé sur ceux du groupe III et particulièrement le sous-type 4 qui présente des caractéristiques intéressantes dans le traitement symptomatique de la douleur et de la maladie de Parkinson. Le manque d’outils pharmacologiques de ce récepteur nous a poussé à synthétiser de nouveaux agonistes orthostériques à partir du composé référence, le LSP4-2022. Cette molécule est issue de nombreuses optimisations chimiques du (S)-PCEP provenant lui d’un screening virtuel. Durant ces trois années de doctorat, nous avons pu peaufiner la relation structure-activité autour du LSP4-2022 en synthétisant des nouveaux analogues fluorés et hétérocycliques. En parallèle, une seconde étude nous a permis d’attribuer la configuration des deux diastéréomères constituants tous les composés testés à ce jour / Glutamate is the major excitatory neurotransmitter in the central nervous system. It is responsible of the majority of synaptic transmissions. In contrast, this natural amino acid is also involved in numerous neuropathologies and particularly in case of glutamate overconcentration in the synapse. Metabotropic glutamate receptors, that can modulate synaptic transmission, thus constitute promising therapeutic targets. These receptors are divided in three groups and our laboratory has been focused in group III and especially subtypes 4 which own interested properties in symptomatic treatment of pain and Parkinson Disease. The lack of pharmacological tools targeting this receptor prompts us to synthesize novel orthosteric agonist from the hit compound LSP4-2022. This molecule was obtained after several chemical optimizations from (S)-PCEP discovered from virtual screening. During my Ph.D., we could refine the structure-activity relationship of LSP4-2022 synthesizing new fluorinated and heterocyclic derivatives. Besides, a second study was carried out to identify the configuration of the two diastereomers which form tested compounds

Les lipopolysaccharides (LPS) sont les constituants majeurs de la membrane externe des bactéries à Gram négatif. Ils sont composés d’un polysaccharide (PS) relié à une région lipidique : le lipide A. Ces structures sont très variables d’une bactérie à l’autre. Elles sont aussi susceptibles de subir des modifications post-traductionnelles par des enzymes en réponse à des stimuli extérieurs. Chaque bactérie possède sa propre signature représentée par la structure unique de ses LPS. Les LPS sont reconnus par le récepteur MD-2 :TLR4. Ce complexe discrimine la structure des lipides A et déclenche de façon structure-dépendante ses voies de signalisation. Les LPS sont très étudiés pour leurs activités néfastes, notamment dans le déclenchement de la cascade inflammatoire qui mène au choc septique. Cependant ils présentent aussi de multiples activités bénéfiques. Dans le cadre de cette thèse, nous avons exploré deux types d’activités bénéfiques des LPS chez l’homme.L’analyse structurale des LPS par spectrométrie de masse est une étape indispensable pour comprendre leurs activités biologiques. Nous proposons deux nouvelles micro-méthodes d’analyse appliquées directement sur les membranes bactériennes. Ceci nous permet d’identifier plus rapidement les molécules de LPS au plus proche de leurs configurations natives, en évitant les artefacts dus à l’extraction. Cette méthode puissante pourra également être développée comme outil de détection rapide de pathogènes.Ensuite, nous avons étudié la relation structure-activité de LPS naturellement peu toxiques mais actifs au niveau cutané. Ce sont des composés du lysat bactérien de Vitreoscilla filiformis contenus dans des crèmes dermatologiques et cosmétiques visant à traiter la dermatite atopique. Les lipides A possèdent des chaînes courtes d’acides gras et les groupes phosphates peuvent être substitués par des groupements phosphoéthanolamines. Les activités biologiques induites par ces LPS prennent place comme des mécanismes de défense pour améliorer la réponse immune et lutter contre les pathogènes.En outre, le pouvoir adjuvant des LPS est l’une de leurs activités bénéfiques les plus étudiées. Les LPS sont naturellement trop toxiques pour être utilisés tels quels. Nous avons, caractérisé des LPS détoxifiés par modifications chimiques, établi et effectué différents tests de « screening » permettant d’évaluer leur adjuvanticité et leur non-pyrogénicité.Enfin, pour des applications thérapeutiques chez l’homme, les LPS doivent être produits en grandes quantités. Nous exposons la compatibilité du procédé de production de la société LPS-BioSciences à l’échelle industrielle et la réglementation des médicaments. Une amélioration de la méthode d’extraction est proposée pour extraire des quantités de l’ordre du gramme. De plus, le procédé de production est réalisable en respectant les bonnes pratiques de fabrication des médicaments. / Lipopolysaccharides (LPS) are the main components of the outer membrane of Gram negative bacteria. They are composed of a polysaccharide moiety linked to a lipid one, the lipid A. These structures are different from one bacterium to the other. They are also able to be modified by enzymatic post-translational modifications in response to external stimuli. Each bacterium possesses its own footprint shown by the unique structure of its LPS. LPS are recognized by the MD-2:TLR4 receptor. This complex distinguishes the lipid A structures and it actives some signalling pathways with a structure dependant manner. LPS are studied for their harmful effects, especially for their implication in the inflammatory cascade leading to septic shock. However, LPS keep multiple beneficial activities. In the context of this thesis, we have explored two kinds of beneficial activities for human.Structural analysis of LPS by mass spectrometry is an indispensable step to understand their biological activities. We propose two new micromethods of analysis directly applied on bacterial membranes. We can identify quickly the LPS molecules as close as possible to their native configurations. Thus, we can check the LPS structures before their extraction. This powerful method could be developed as a rapid tool for pathogens detection.Then, we studied the structure-activity relationships of naturally low-toxic, but active LPS at the skin level. They are compounds of the Vitreoscilla filiformis bacterial lysate. This lysate is used in dermatological and cosmetic creams to treat atopic dermatitis. Lipids A are composed of short fatty-acid chains (10 and 12 carbons), and the phosphate groups can be substituted by ethanolamine-phosphate. The biological activities induced by these LPS take place as defense mechanisms to improve the immune response against pathogens.Moreover, the adjuvant capability of LPS is another well studied beneficial activity. LPS are naturally too toxic to be used as vaccine adjuvant. We characterized chemically detoxified LPS and we established and realized different « screening » tests to evaluate their adjuvanticity and non-pyrogenicity.Finally, for human therapeutic applications, LPS must be produced on a large scale. We exposed the compatibility between the LPS-BioSciences process of production at the industrial scale and the medical regulation. One improvement of the extraction method is proposed in order to extract about one gram of LPS. The process is compatible with the good manufacturing practices.

The war between human and malaria has never stopped, and the development and application of antimalarial drugs has not eradicated this terrible disease. To fight drug-resistant malaria, many leads have been studied over the years. (1S,3R)-MMV008138 and MMV1803522 are two compounds that have been studied in the Carlier Group. My research focused on the structural variation of each of these compounds, in the hope that greater potency could be realized. Chapter 2 describes my work on (1S,3R)-MMV008138, which inhibits the enzyme PfIspD in the methylerythritol phosphate (MEP) pathway. This compound shows good in vitro potency against the drug resistant Dd2 strain of Plasmodium falciparum. However, this lead showed no activity in mouse models. This lack of activity may be due to poor metabolic stability of the compound. However, a significant increase in in vitro potency could also improve in vivo activity. Towards that end, I focused on further variation of the D-ring and A-rings. With the regard to the D-ring, we made five analogs of MMV008138 that replaced the 2,4-dichlorophenyl ring with dihalogenated thiophen-3-yl and thiophen-2-yl rings. We also explored the effect of installing a cyano group on the A-ring of MMV008138. Unfortunately, none of these new compounds were potent growth inhibitors of Dd2 strain P. falciparum. We conclude that the lead goes into a well-defined pocket within the PfIspD enzyme that only accommodates 2,4-dihalogenated phenyl D-rings. This pocket also cannot accept any substitution larger than F on the A-ring. Interestingly, the crystal structure of 5-cyano-substituted MMV008138 was obtained ((±)-2-50c). This is the first compound out of more than 100 analogs of MMV008138 family to be amenable to crystallization. The solid state conformation of the (±)-2-50c revealed that the C3-carboxyl group was in a pseudoequatorial orientation, and the C1-aryl group was thus in a pseudoaxial orientation. 1H NMR spectroscopic studies in CD3OD-D2O were carried out to determine the solution conformation. As expected from previous studies of ester derivatives of MMV008138, these studies indicated that in solution, 2-5 would adopt both the C3-carboxyl pseudoequatorial and pseudoaxial conformations. In Chapter 3, I describe the synthesis of analogs of the antimalarial drug candidate MMV1803522. This β-carboline-3-carboxamide shows good in vitro growth inhibition potency of Dd2 strain P. falciparum, operating by a still unknown mechanism. To investigate the pharmacophore of this lead, I first sought to determine whether the pyridine N (i.e. N2) of the β-carboline was important for in vitro potency. I prepared series of carbazole analogs of MMV1803522, which replace N2 with a CH. These compounds potently inhibited the growth of Dd2 strain P. falciparum. These results suggest that N2 of MMV1803522 is not involved in any energetically significant interactions with its target protein. To further identify the pharmacophore, we prepared truncated analogs lacking the A- and B- rings (biphenyl analogs), and tricyclic analogs that feature a reversed indole moiety. Unfortunately, the biphenyl analogs and reversed indole analogs show no growth inhibition at 10,000 nM the highest concentration tested. Lastly, I describe analogs of MMV1803522 in which the 3,4-dichlorophenyl ring of MMV1803522 was replaced with halogenated thiophene. This substitution was tolerated, but compounds were roughly half as potent as MMV1803522. / Doctor of Philosophy / Malaria, mainly caused by the infection of P. falciparum, is a serious worldwide disease. In 2020, there were 241 million cases of malaria infections and over 600,000 deaths from malaria. Combinations of commercially available antimalarial compounds, such as chloroquine, mefloquine and artemisinin, are commonly used as combination therapies to treat malaria. Since different antimalarial compounds have different mechanisms of action, this combination strategy can greatly slow down the spread of drug-resistant parasites. However, multiple drug-resistant strains of P. falciparum have been reported. Therefore, there is an urgent need for new antimalarial compounds with novel mechanisms of action. This dissertation involves my research on the investigation and optimization of two novel antimalarial compounds, MMV008138 and MMV1803522. MMV008138 is an inhibitor of the MEP pathway, which is an essential metabolic pathway and attractive target for antimalarial therapies, in malaria parasites. The parasites cannot survive, with the MEP pathway inhibited. Since the MEP pathway is not present in human, the MMV008138 molecule is unlikely to have toxicity to human. The MMV008138 molecule has been demonstrated to have great in vitro performance of inhibiting the MEP pathway in several studies, however, the in vivo performance in mouse models is yet to improve. This may be due to the poor metabolic stability of this compound. The compound decomposes in the mouse body before it takes effect. To enhance the metabolic stability and potency, I performed chemical modifications on the A- and D-rings of the MMV008138 compound. An X-ray crystal structure was obtained to help elucidate the conformer distribution of MMV008138. This crystal structure can be used to guide our understanding of the docking of this compound to the target enzyme in the future. MMV1803522 is another compound that shows great potency in vitro and in vivo. This compound is fully oxidized and contains four aromatic rings. However, the target enzyme and the mechanism of action of MMV1803522 is yet to be discovered, and the structure-activity relationship between the chemical structure and the biological activity of this molecule is still unknown. Therefore, I have developed synthetic methods to synthesize a series of compounds that are structurally similar to the MMV1803522 and found that potency of this molecule is not due to the nitrogen on the C-ring. Also, the number and size of the ring structures in the MMV1803522 may be crucial for this molecule to exhibit great potency in vitro and in vivo.

No description available.

No description available.

Binding of the Rev protein with Rev Response Element (RRE) RNA present in singly- and unspliced mRNA transcripts is necessary for the replication of HIV-1. This interaction transports the mRNA transcripts from the nucleus to the cytoplasm for translation of the necessary structural and enzymatic proteins for the newly budding virus as well as for providing its genetic material. Given the high rate of mutation in HIV-1, the highly conserved and pertinent RRE RNA is of high interest for pharmaceutical intervention. Consequently, a branched peptide library containing unnatural amino acids was developed to target RRE RNA with the goal of increasing stability, potency, selectivity, and in vivo activity for RRE RNA. An unnatural amino acid branched peptide library (46,656 sequences) was synthesized and screened against RRE IIB and several hits in the sub-micromolar regime were found. A number of hits demonstrated selectivity in the presence of other RNAs in addition to two hits, 4A5 and 4B3, significantly inhibiting HIV-1 growth in vitro. These peptides inhibited HIV-1 replication in a concentration dependent manner and were demonstrated to be non-toxic. Further analysis of 4A5 and 4B3 via footprinting and SHAPE-MaP experiments determined that these peptides blocked binding of Rev through binding at the primary and secondary binding sites of RRE RNA. Sphingosine 1-phosphate (S1P) is a signaling molecule that plays a role in various biological processes including immunity, neurogenesis, and angiogenesis. The role S1P plays is largely determined by its location, in which Spinster homolog 2 (spns2) and mfsd2b are the two known transporters. The two transporters exist in different cell types and cellular localizations, with spns2-produced S1P being responsible for trafficking of lymphocytes. As such, spns2 has become of interest for therapeutic targeting in autoimmune and inflammatory diseases. To validate spns2 as a target in pharmaceutical intervention, a series of spns2 inhibitors were developed. A screening of a library of inhibitors found that compound SLP7120922 demonstrated inhibition of spns2 transport activity. The design, synthesis, and biological evaluation of inhibitors based on SLP7120922 is described. Modifications to the lipophilic tail region were performed with one compound 4.40f discovered to be potent, minimally toxic, and active in vivo. A series of modifications to the head region were then conducted that evaluated linear head derivatives with alkyl-, amide-, and amino acid-based groups. A number of compounds are reported that demonstrate good in vitro activity and minimal toxicity with two compounds, 4.48b and 4.52c, showing favorable in vivo activity in mice. / Doctor of Philosophy / Human immunodeficiency virus (HIV-1) has a high rate of mutation, which commonly leads to the need for many types of medications throughout the lifetime of a patient. In order to design a therapeutic that the virus has a low chance of growing resistance to, a target needs to be chosen with a low mutation rate. One such target is the Rev Response Element (RRE) RNA and it is necessary for the virus to replicate. A protein named Rev binds to RRE RNA in order for RRE to carry out its pertinent function. To block this function we have chosen branched peptides to target the RNA. Peptides are made of the same building blocks of proteins, but are much shorter than proteins. The peptides described here are made up of modified building blocks, called unnatural amino acids. This work describes the generation of an unnatural amino acid branched peptide library and how it was screened in order to find branched peptides that bind RRE RNA. Many peptides were found to bind RRE RNA but two in particular, 4A5 and 4B3, were the best binders that inhibited HIV-1 growth. The remainder of the work describes how these peptides bind to RRE RNA, while demonstrating that they are non-toxic and bind HIV-1 in a concentration dependent manner. A transporter protein termed Spinster homolog 2 (spns2) transports a signaling molecule known as sphingosine 1-phosphate (S1P). For our immune system to function properly, spns2 has to transport S1P to the appropriate places to signal to immune cells. Unfortunately, this is a problem in autoimmune and inflammatory diseases, such as multiple sclerosis, due to these diseases having an overactive immune system. A potential way to treat these diseases would be by inhibiting spns2. This work describes the design, synthesis, and biological evaluation of spns2 inhibitors. Many compounds were found to inhibit spns2 to a degree, but three compounds, in particular, show potent and effective inhibition in mice.

Doctor of Philosophy / In healthy individuals, the autoimmune system is the body's natural defense against foreign materials and organisms. The main tools utilized for this defense mechanism are immune cells. However, in patients suffering from autoimmune diseases, the autoimmune system is overactive resulting in its attack on healthy cells, which leads to reduced or eliminated function of the targeted organs. To suppress these overreactive immune responses, pharmaceutical intervention is needed. An integral part of autoimmune response is the lipid sphingosine-1-phosphate (S1P). Interactions of S1P with its response-inducing receptors prompts the release of immune cells, lymphocytes in particular, from lymph tissue to migrate and participate in the invoked immune response. The pharmaceutical industry has produced five FDA approved drugs that disrupt this S1P-receptor interaction by blocking the receptor to reduce the autoimmune response in patients suffering from autoimmune diseases such as multiple sclerosis and ulcerative colitis. However, these treatments had adverse side effects on the cardiovascular system due to the presence of S1P receptors in the heart. Due to this, there is attraction to target a different node of the S1P signaling pathway to avoid these side effects while still suppressing the immune response. A node that is a viable target for therapeutic target that has recently become the focus of medicinal chemistry campaigns is the transporter protein spinster homolog 2 (Spns2). This protein is responsible for the transport of S1P from intracellular space to extracellular space to interact with its receptors and induce the immune response. Recently, our group has developed several effective inhibitors of Spns2. In this dissertation, several improvements of previously reported inhibitors are revealed. The pinnacle of this work is the development of 4.22v that is optimized to have drug-like properties for testing in mice. Administration of 4.22v to mice resulted in reduced circulating lymphocytes and without showing signs of toxicity following chronic dosing for 14 days. These results suggest that 4.22v is a potential drug candidate and is currently undergoing further biological evaluation.

No / The protein O6-alkylguanine-DNA alkyltransferase (Atase) is responsible for the repair of DNA lesions generated by several clinically important anti-cancer drugs; this is manifest as active resistance in those cancer cell lines proficient in Atase expression. Novel O6-substituted guanine analogues have been synthesized, bearing acidic, basic and hydrogen bonding functional groups. In contrast to existing O6-modified purine analogues, such as methyl or benzyl, the new compounds were found to resist repair by Atase even when tested at concentrations much higher than O6-benzylguanine, a well-established Atase substrate active both in vitro and in vivo. The inactivity of the new purines as covalent substrates for Atase indicates that agents to deliver these groups to DNA would represent a new class of DNA-modifying drug that circumvents Atase-mediated resistance.

Diseases such as malaria and dengue impose great economic burdens and are a serious threat to public health, with young children being among the worst affected. These diseases are transmitted by mosquitoes, also called disease vectors, which are able to transmit both parasitic and viral infections. One of the most important strategies in the battle against mosquito-borne diseases is vector control by insecticides and the goal is to prevent people from being bitten by mosquitoes. Today’s vector control methods are seriously threatened by the development and spread of insecticide-resistant mosquitos warranting the search for new insecticides. This thesis has investigated the possibilities of vector control using non-covalent inhibitors targeting acetylcholinesterase (AChE); an essential enzyme present in mosquitoes as well as in humans and other mammals. A key requirement for such compounds to be considered safe and suitable for development into new public health insecticides is selectivity towards the mosquito enzyme AChE1. The work presented here is focused on AChE1 from the disease transmitting mosquitoes Anopheles gambiae (AgAChE1) and Aedes aegypti (AaAChE1), and their human (hAChE) and mouse (mAChE) counterparts. By taking a medicinal chemistry approach and utilizing high throughput screening (HTS), new chemical starting points have been identified. Analysis of the combined results of three different HTS campaigns targeting AgAChE1, AaAChE1, and hAChE allowed the identification of several mosquito-selective inhibitors and a number of compound classes were selected for further development. These compounds are non-covalent inhibitors of AChE1 and thereby work via a different mechanism compared to current anti-cholinergic insecticides, whose activity is the result of a covalent modification of the enzyme. The potency and selectivity of two compound classes have been explored in depth using a combination of different tools including design, organic synthesis, biochemical assays, protein X-ray crystallography and homology modeling. Several potent inhibitors with promising selectivity for the mosquito enzymes have been identified and the insecticidal activity of one new compound has been confirmed by in vivo experiments on mosquitoes. The results presented here contribute to the field of public health insecticide discovery by demonstrating the potential of selectively targeting mosquito AChE1 using non-covalent inhibitors. Further, the presented compounds can be used as tools to study mechanisms important in insecticide development, such as exoskeleton penetration and other ADME processes in mosquitoes.